Key result
A decision analysis model for AF patients recommends no treatment for CHA2DS2-VASc <2, warfarin for scores 2-4 with low HAS-BLED scores, and aspirin for scores ≥5 when HAS-BLED is ≥4.
Why the study?
Does warfarin or aspirin maximize the annual probability of not having a stroke and not having a major bleed in patients with chronic non-valvular atrial fibrillation compared to no therapy?
Population
Patients with chronic non-valvular atrial fibrillation
Comparison
Warfarin or aspirin vs No therapy
Design
Other
Authors
Loading...
Decision model supports risk-stratified antithrombotic choice in AF; leaves open prospective validation before practice change.
Does warfarin or aspirin maximize the annual probability of not having a stroke and not having a major bleed in patients with chronic non-valvular atrial fibrillation compared to no therapy?
A decision analysis model demonstrates how combining CHA2DS2-VASc and HAS-BLED scores can guide the choice between warfarin, aspirin, and no therapy in non-valvular atrial fibrillation.
Romero‐Ortuño et al. (2011) studied chronic non-valvular atrial fibrillation. Warfarin or aspirin vs. No therapy was evaluated on Annual probability of not having a stroke and not having a major bleed. A decision analysis model for AF patients recommends no treatment for CHA2DS2-VASc <2, warfarin for scores 2-4 with low HAS-BLED scores, and aspirin for scores ≥5 when HAS-BLED is ≥4.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: